Seagen, Astellas report positive results from PADCEV phase 2 trial in advanced urothelial cancer

Seagen, Astellas report positive results from PADCEV phase 2 trial in advanced urothelial cancer

Submitted by admin on October 13, 2020 - 11:08am
Source: 
Pharmaceutical Business Review
News Tags: 
Seagen
Astellas
clinical trials
EV-201
urothelial cancer
Headline: 
Seagen, Astellas report positive results from PADCEV phase 2 trial in advanced urothelial cancer
snippet: 

Seagen and Astellas Pharma announced positive topline results from the second cohort of patients in the pivotal phase 2 single-arm clinical trial known as EV-201.

Do Not Allow Advertisers to Use My Personal information